clinical trial · NCT05668585
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
Solid TumorsMelanomaNSCLCCRCATCCFT1946TrametinibCetuximab
brief summary
The purpose of this study is to evaluate the safety and tolerability of CFT1946 as well as to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CFT1946 as monotherapy (Arm A) and in combination with trametinib (CFT1946 + trametinib; Arm B) or Cetuximab (CFT1946 + cetuximab; Arm C).
started
Dec 8, 2022
primary completion
Nov 5, 2025
completion
Nov 5, 2025
last updated
Nov 21, 2025
official title
A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol